title: Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy--United States, July-November 2002.
abstract: In the United States, pharmacists compound medications to meet unique patient drug requirements or to prepare drug products that are not available commercially. In September 2002, the North Carolina Division of Public Health (NCDPH) was notified of two cases of meningitis caused by a rare fungus in patients who had received epidural injections at outpatient pain management clinics. This report describes five cases of fungal infection associated with contaminated drugs prepared at a compounding pharmacy. Clinicians should consider the possibility of improperly compounded medications as a source of infection in patients after epidural or intra-articular injections.
mesh_terms: D000368:Aged; D004339:Drug Compounding; D004340:Drug Contamination; D005093:Exophiala / Q000302:isolation & purification*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007268:Injections, Epidural; D008581:Meningitis / Q000453:epidemiology / Q000209:etiology*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077555:Methylprednisolone Acetate; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology*; D009657:North Carolina / Q000453:epidemiology; D014481:United States
chemical_list: D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone